Sun Pharma to acquire Russia's JSC Biosintez; shares up

“With this move, we plan to acquire the product portfolio and local manufacturing capability in Russia which would help in expanding our presence in Russia and serving Russia pharmaceutical market more effectively,” Sun Pharma said in a statement.

Sun Pharma to acquire Russia's JSC Biosintez; shares
The deal will involve cost acquisition of approximately RUB 1526 million ($24 million).Photo: Reuters/ Danish Siddiqui

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x